The successful fundraising reflects a growing interest and confidence in the Canadian life sciences sector among institutional investors.

Genesys Capital, a Toronto-based venture capital firm, has successfully closed its fourth venture fund, named Genesys Ventures IV, aimed at enhancing life sciences innovation in Canada.

The closing of Genesys Ventures IV enables Genesys Capital to continue its mission of building and supporting Canadian life sciences companies.

This fund has attracted commitments from several key institutional investors, including HarbourVest Partners and prominent Canadian organizations such as Fonds de solidarité FTQ, BDC Capital, Export Development Canada, Teralys Capital, and Venture Ontario.